JG
LGND icon

Jefferies Group’s Ligand Pharmaceuticals LGND Stock Holding History

Jefferies Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-40,075
Closed -$1.68M – 2243
2014
Q1 		$1.68M Buy
+40,075
New +$1.67M 0.02% 682

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Jefferies Group's LGND Position: Q3 2021 in Review

Jefferies Group sold out of Ligand Pharmaceuticals (LGND) in Q3 2021, closing a stake of 37,621 shares — an estimated $3.08M sold.

Jefferies Group first reported a position in LGND in Q1 2014 and held it in 11 quarters. The position peaked at $9.37M in Q2 2018. 207 funds tracked by Wall St. Rank hold LGND as of Q3 2021.

  • Jefferies Group reported no remaining Ligand Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Jefferies Group sold 37,621 Ligand Pharmaceuticals shares in Q3 2021, an estimated $3.08M.
  • Jefferies Group first reported a position in Ligand Pharmaceuticals in Q1 2014 and held it in 11 quarters.
  • Jefferies Group's Ligand Pharmaceuticals position peaked at $9.37M in Q2 2018.
  • 207 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2021.

Based on Jefferies Group's 13F filing for Q3 2021, filed 15 Nov 2021.